– Advertisement – California voters decided Tuesday that Uber and Lyft should be exempt from state labor law that aimed to make their drivers employees rather than contractors, according to projections from NBC News.Voters made the call on California’s Proposition 22, a ballot measure that essentially became one of Uber and Lyft’s last hopes in the state to continue their operations under the status quo.The proposition would allow drivers for app-based transportation and delivery companies to be classified as independent contractors in many circumstances. While that would disqualify them for benefits granted to employees, the measure also entitles drivers to new benefits like minimum earnings and vehicle insurance.- Advertisement – – Advertisement – While Uber and Lyft were able to raise gobs of cash from venture capitalists while private and have multi-billion dollar valuations on the public market, neither has reached profitability. That makes the contractor-driver model especially important to the businesses, allowing them to avoid costly benefits associated with employment, such as unemployment insurance.The companies have warned they’d likely have to pass on increased costs of worker reclassification to consumers. Uber estimated in a blog post earlier this year that it would have to raise rider prices between 25% and 111% in parts of California to cover the costs.The New York Times reported in August that both companies were considering a fleet-like model, similar to traditional taxis. Under that model, the companies would license their brands to operators like a franchise, according to the Times.The proposition has significant implications for DoorDash and Instacart as well, both of which are reportedly preparing to go public. Like Uber and Lyft, these companies also rely heavily on gig workers for their delivery services. Without the passage of Proposition 22, the companies would likely worry about potentially larger expenses to hire workers as employees.Critics like Rep. Ro Khanna, D-Calif., have said that there’s nothing written into current labor law stopping Uber and Lyft from providing flexibility to drivers while classifying them as employees. The companies have countered that the logistics of such a model would be untenable since it would be too difficult to track time worked.The companies faced a setback in August when a trial judge granted a preliminary injunction forcing them to reclassify their drivers as employees, although that ruling has yet to go into effect as the case makes its way through the legal process. The lawsuit’s fate is unclear now that the ballot measure has passed.Representatives from Uber, Lyft and the California attorney general’s office did not immediately respond to requests for commentWATCH: Uber, Lyft spend millions on campaign to protect their business in California Several gig economy apps backed the measure, including Uber, Lyft, DoorDash, Instacart and Postmates, which Uber is acquiring. The support from these companies helped raise nearly $203 million to back the measure, while opponents raised less than $20 million, according to tallies compiled by Ballotpedia.Democratic presidential nominee Joe Biden opposed the measure. Biden tweeted in May that Californians should vote no on the initiative and said, “gig economy giants are trying to gut the law and exempt their workers. It’s unacceptable.”- Advertisement – Dara Khosrowshahi, chief executive officer of Uber Technologies Inc., speaks during an interview in Tokyo, Japan, on Wednesday, July 3, 2019.Akio | Bloomberg | Getty Images
Willock form hard for Arteta to ignore If you thought Celtic’s poor form was behind them then think again. The stark reality is their European campaign has been a disaster and is now on the brink. Still winless after three games, there will be some pretty strong and searching questions for Neil Lennon and his team to answer after this display.They were limp and lacklustre as Sparta Prague – decimated by injuries and health problems relating to positive Covid tests – came away from Celtic Park with an emphatic 4-1 victory. It was a convincing win for the Czech side. Forget progressing to the round of 32 on this evidence.Lennon put his faith in the same 11 starters that saw off Aberdeen to reach the Scottish Cup final but it is now one win in their last six games. This made it three home defeats for the first time in 30 years. Sparta arrived in Glasgow off the back of two heavy defeats themselves in Group H, but left looking like world-beaters.Celtic may be chasing a fourth domestic treble in a row but when it comes to facing even the most modest of European opponents, they have fallen short time and time again.Ben GroundsCeltic fixturesSun Nov 8: Motherwell (a)Sun Nov 21: Hibernian (a)Thurs Nov 26: Sparta Prague (a)Thurs Dec 3: AC Milan (a)Sun Dec 6: St Johnstone (h)Thurs Dec 10: Sparta Prague (a)Sun Dec 13: Kilmarnock (h) “Keep doing what he’s doing consistently, and his chance will arrive.”That was Mikel Arteta’s response when asked what Joe Willock has to do to get a chance in the Premier League, but after another excellent display in the Europa League, the 21-year-old, who has drawn comparisons to former Arsenal midfielder Aaron Ramsey, is firmly knocking on his manager’s door to be included in the club’s Premier League squad.- Advertisement – Image:Kelechi Iheanacho celebrates with Leicester City team-mates after putting them 2-0 up against Braga Arsenal fixturesSun Nov 8: Aston Villa (h)- Advertisement – Rangers fans, players and manager Steven Gerrard must all be delighted, and relieved, Alfredo Morelos’ muted summer transfer to Lille never materialised, with the striker seemingly back to his best after a slow start to the season.At the Estadio da Luz, Morelos, 24, found himself in the right place, at the right time, to touch home James Tavernier’s cross for a record-breaking 22nd European goal in just 37 games for Rangers, overtaking club legend Ally McCoist in the process. All this from a player who cost just £1m from HJK Helsinki in June 2017, with the striker having since scored a hugely impressive 84 goals in 154 games, making it one of the best pieces of business in the club’s history.Richard MorganRangers fixturesSun Nov 8: Hamilton (h)Sun Nov 22: Aberdeen (h)Thurs Nov 26: Benfica (h)Thurs Dec 3: Standard Liege (h)Sun Dec 6: Ross County (a)Thurs Dec 10: Lech Poznan (a)Celtic turn Sparta into world-beaters There was certainly a feeling of an opportunity lost when Leicester missed out on a Champions League spot on the final day of last season; not just for being absent from Europe’s top table, but also because it seemed like it might be a chance they would not get again.Nearly four months on, things have changed. The Foxes are a point off the top of the Premier League and at full steam in their Europa League group, after a stunning 4-0 thrashing of Braga at the King Power Stadium on Thursday.That alone would be impressive, more so given the injury problems Brendan Rodgers faces, and even more so having given star striker Jamie Vardy a night off.Momentum is a funny thing, and while Leicester might have lost it in the second half of last season, they looked like a team without a worry in the world after half-time against Braga.The quality of their football was stunning, James Maddison looked like getting back to his sharpest and Cengiz Under appeared to be striking up a potent partnership with him in their new-found 3-4-3.There’s a long way to go in this competition, and you do not win anything for topping your group, something the Foxes look likely to do already. But the way in which they have gone about their opening three games has been undeniably impressive.Ron WalkerLeicester fixturesSat Nov 8: Wolves (h)Thurs Nov 26: Sporting Braga (a)Sat Nov 28: Fulham (h) TBCThurs Dec 3: Zorya Luhansk (a)Sat Dec 5: Sheff Utd (a) TBCThurs Dec 10: AEK Athens (a)Sun Dec 13: Brighton (h) TBCRecord-breaking Morelos back to his best Image: Celtic endured a difficult night Thurs Nov 26: Molde (a)Sat Nov 28: Wolves (h) TBCThurs Dec 3: Rapid Vienna (h)Sat Dec 5: Tottenham (a) TBCThurs Dec 10: Dundalk (a)Sat Dec 12: Burnley (h) TBCLo Celso stars, but Jose wants more Willock was an absentee from Arsenal’s 18-man squad at Old Trafford, but after two man-of-the-match displays in the Europa League and two goals in as many games in the competition, he is certainly doing all the right things.Full of energy and running, Willock continually popped up in goal scoring positions and he played key roles in Arsenal’s first and second goals before putting the finishing touch on another fine display with an emphatic finish.Will it be enough for him to get a chance when Arsenal take on Aston Villa in the Premier League on Sunday, live on Sky Sports Box Office? Willock’s Europa League form will be difficult for Arteta to ignore, especially with Arsenal’s struggles to break down Leicester at the Emirates Stadium fresh in the memory.- Advertisement – – Advertisement – Image:Giovani Lo Celso celebrates scoring Tottenham’s third goal Image:Alfredo Morelos is back to his best with Rangers He could do better because he has the talent to be at the top level. He understands that every single day and for me, it’s a pleasure to play with him, especially because he’s humble. He has a great present and a great future.David Luiz on Joe Willock Image:Joe Willock is impressing for Arsenal in the Europa League Giovani Lo Celso has had a stop-start career at Tottenham. At times he’s looked a world-class player but chances have been in short supply this season.Jose Mourinho traditionally prefers his engine room to have steel rather than silk and, as a result, Lo Celso only has had one start in the Premier League to his name this season. The Argentine was also one of the four players hooked at half- time by a fuming Mourinho in the previous Europa League encounter at Antwerp. He was given a chance to redeem himself at Ludogorets and he grabbed it.Lo Celso’s attitude in midfield set the tone. He was zipping around the pitch in tenacious fashion, linking with the front three impressively with his trademark cute passing. His goal was more about the excellent assist from Heung-Min Son than his easy finish, but the Argentine deserved to have his moment after a mature performance.Whether it was enough to force his way into the Premier League picture is another matter. Mourinho was not in the mood for getting carried away with Lo Celso, questioning his fitness. When asked to analyse his performance, Mourinho said: “Good with the ball and not very good without the ball. His physical condition is not good.”Lewis JonesTottenham fixturesSun Nov 8: West Brom (a)Sat Nov 21: Man City (h)Thurs Nov 26: Ludogorets (h)Sat Nov 28: Chelsea (a) TBCThurs Dec 3: LASK (a)Sat Dec 5: Arsenal (h) TBCThurs Dec 10: Antwerp (h)Sat Dec 12: Crystal Palace (a) TBCLeicester continue to compound the critics Willock offers Arsenal something very different and even if it’s only as an option from the bench this weekend, his form deserves rewarding.
Kolanovic, the bank’s head of macro quantitative and derivatives strategy, said a possible Joe Biden presidency with a split Congress could result in a market-friendly environment with lower taxes, status-quo regulations, a better U.S.-China trade relationship. He called this outcome “one of the most favorable scenarios for the market.”“A GOP senate majority should ensure that Trump’s pro-business policies stay intact (tax code, deregulation), and if Biden is confirmed we should be able to expect an easing of the trade war (which should boost global trade and corporate earnings growth),” Kolanovic said in a note to clients on Friday.Kolanovic, the No.1 equity strategist ranked by Institutional Investor magazine, was one of the few on Wall Street that correctly called the market bottom in March and the subsequent rebound to new record highs. – Advertisement – (This story is for CNBC Pro subscribers only.)JPMorgan’s top-rated equity strategist Marko Kolanovic believes the election outcomes are shaping up to be “the best of both worlds for stocks,” calling for a sustainable rally for the market.- Advertisement – – Advertisement –
Pfizer and BioNTech said on Monday their Covid-19 vaccine is more than 90% effective at preventing trial participants from contracting the coronavirus, sending parts of the stock market soaring. Traders are riding the rally through certain exchange-traded funds and stock plays.Both the Dow Jones Industrial Average and S&P 500 hit intraday all-time highs on Monday. The move higher on Monday was characterized by a rotation out of Big Tech names and companies that had benefited from people staying at home and into beaten-down cyclical names that were hit hard by the coronavirus.That rotation was continuing Tuesday with Dow futures higher and Nasdaq futures lower. A medical worker stands at the entrance to the New York Stock Exchange (NYSE) on the first day that traders are allowed back onto the historic floor of the exchange on May 26, 2020 in New York City.Spencer Platt – Advertisement – – Advertisement – – Advertisement –
Nov 24, 2004 (CIDRAP News) The US Department of Agriculture (USDA) ended 6 days of suspense for the beef industry by announcing late yesterday that a cow suspected of having bovine spongiform encephalopathy (BSE) didn’t have the disease after all. Nov 23 USDA statement Lyons noted that the USDA has said that more BSE cases may be found, but added, “Beef is safe from BSE because anything that could potentially carry BSE is prohibited from entering the food supply.” USDA BSE information and resources The USDA and Food and Drug Administration have banned the use of high-risk cattle parts such as the brain and spinal cord, called specified risk materials (SRMs), in human food. But Foreman said the ban still permits the use of some potentially hazardous material, such as the sheath (dura) that covers the spinal cord, and slaughter plants can use the same blades for removing SRMs and for processing meat without sterilizing them in between. She also charged that the rules are not well enforced. “The USDA National Veterinary Services Laboratories (NVSL) in Ames, Iowa, has determined that the inconclusive screening test sample reported on Nov 18 has tested negative for BSE upon confirmatory testing,” said John Clifford, deputy administrator of the Animal and Plant Health Inspection Service (APHIS). The National Cattlemen’s Beef Association (NCBA) said the latest case shows that measures to protect the public from exposure to BSE are working. “This animal never entered the human food supply, nor did it enter the animal feed chain, proving the systems in place are working to protect public and animal health,” said NCBA Vice President Jan Lyons, a Manhattan, Kan., cattle producer, in a prepared statement. Clifford said that to be safe, the USDA ran two immunohistochemistry (IHC) tests, known as the “gold standard” test for BSE, on the cow. The first negative result came Nov 22. “Because the Nov 18 screening test results were reactive in both the first and second screens, NVSL scientists made the recommendation to run the IHC test a second time,” he said. “On Nov 23 they reported the second IHC test was negative. Negative results from both IHC tests make us confident that the animal in question is indeed negative for BSE.” Carol Tucker Foreman of the Consumer Federation of America, a leading critic of government food safety policies, said yesterday’s announcement is “good news and a relief for everyone,” but added that the system for protecting the public from BSE still has a number of gaps. The USDA did not reveal where the cow came from or any other details about it. The agency said earlier that the carcass was kept out of the food and animal feed production chains. Two screening tests on the cow had been inconclusive, prompting the USDA to announce the findings Nov 18 and send samples to the NVSL for confirmatory tests. This was the third cow for which screening tests were inconclusive since the USDA expanded its BSE surveillance program June 1. See also: The agency expanded its BSE surveillance this year in response to the discovery of the nation’s first BSE case in a cow in Washington state last December. Beef prices dropped in late June when the USDA announced the first two suspected BSE cases on the basis of single screening tests, but further tests ruled out both cases a few days later. In August the agency announced that henceforward it would announce a suspected case only after two inconclusive tests on the same animal. When the suspected case was announced last week, beef prices weathered the storm better than they did the last time, according to an Associated Press report. Beef futures prices on the Chicago Mercantile Exchange dropped from 87.3 cents to 84.2 cents a pound, but they recovered to 87.25 cents as of yesterday, the report said.
Jul 5, 2006 (CIDRAP News) – In an update on pandemic influenza preparedness efforts, the federal government said last week it had stockpiled enough vaccine against H5N1 avian influenza virus to inoculate about 4 million people and enough antiviral medication to treat about 6.3 million.Health and Human Services (HHS) Secretary Mike Leavitt said his department has stockpiled about 8 million doses of H5N1 vaccine. “Given a two-dose vaccination schedule, this would allow vaccination of 4 million people,” Leavitt wrote in a 12-page report.The report outlines the status of federal efforts to boost US flu vaccine production capacity, increase the stockpile of antiviral drugs, monitor the spread of avian flu in the United States, and assist states with pandemic planning. The report is a follow up to a March report that announced the government’s initial plan for boosting the nation’s supply of avian influenza vaccines and treatments.The H5N1 vaccine being stockpiled now is based on a virus isolated from a Vietnamese patient in 2004 (a clade 1 virus), Leavitt noted. He said a second H5N1 vaccine under development is based on an H5N1 strain that was collected in Indonesia in 2005 (clade 2 virus) and has circulated in Europe, Africa, and parts of Asia.”While the efficacy of these pre-pandemic vaccines cannot be predicted, there is reason to believe they may provide some level of protection for priority personnel and those at greatest risk,” Leavitt wrote.Boosting antiviral stockpilesLeavitt reported that as of Jun 1, the Strategic National Stockpile (SNS) of antiviral drugs contained about:6.2 million treatment courses of oseltamivir (Tamiflu) capsules, with an additional 15.4 million courses expected by the end of December8,600 courses of Tamiflu oral suspension84,000 courses of zanamivir (Relenza), with an additional 3.9 million courses expected by the end of DecemberIn sum, the stockpile is expected to reach 26 million antiviral drug courses by the end of 2006. At least 20 million courses are earmarked for states for distribution in proportion to population, the report says. Up to 6 million courses are reserved for mass prophylaxis in isolated community outbreaks.HHS received a $170 million appropriation to provide a subsidy to states and other jurisdictions that will allow them to buy up to 31 million treatment courses of antiviral medications at 25% off the federal contract price.HHS also will spend $162 million to stockpile other medical supplies, including 6,000 ventilators, 100 million N95 respirators, and 50 million surgical masks, plus face shields, gowns, and gloves, Leavitt reported. So far the department has amassed 20.2 million respirators and 12.3 million surgical masks.Investing in vaccinesIn May, federal officials awarded more than $1 billion worth of contracts for cell-based vaccine technology. Leavitt wrote that reliance on traditional egg-based vaccine production is problematic because an avian flu outbreak, and the poultry culling that would follow, would jeopardize the supply of eggs needed to produce the vaccine. He said vaccine-production cell lines can be frozen indefinitely and that, in comparison with eggs, can more rapidly be used to produce vaccines in the event of a pandemic.Contracts for cell-based vaccine production went to five companies: Solvay Pharmaceuticals ($299 million), GlaxoSmithKline ($275 million), Novartis Vaccines & Diagnostics ($221 million), MedImmune ($170 million), and DynPort Vaccine ($41 million).Another HHS goal is to expand the nation’s capacity for producing the traditional egg-based vaccine. Leavitt wrote that this summer the HHS will issue requests for proposals (RFPs) for building new facilities or retrofitting existing ones.HHS also has issued RFPs for antigen-sparing vaccine technologies that would stimulate protection using a smaller amount of the vaccine, the report says.Coordinating state preparednessCongress allocated $350 million this year to assist with state and local pandemic preparedness. Of this amount, Leavitt said $100 million has already been earmarked to help states identify gaps in preparedness. They are now submitting applications for how they will spend $250 million, which is intended to cover the cost of ranking gaps and making plans for addressing them, developing plans for distributing antiviral drugs, and designing pandemic response exercises.Leavitt said HHS has convened state summits in 48 states, and the remaining two have summits scheduled. He added that many states have progressed to the next step of holding interstate and regional planning meetings.This fall HHS will begin holding risk-communication training sessions for state and local public health professionals and community leaders in 10 HHS regions. “State by state, we are moving from awareness to preparedness,” Leavitt wrote.Other developmentsLeavitt’s report describes several other elements of federal pandemic planning activities, including:International cooperation: The nation has pledged $334 million to assist nations most severely affected by avian influenza. In May, HHS shipped Tamiflu to a secure location in Asia to help contain a pandemic. (If containment is not possible, the drug would be sent back to the US.)Domestic monitoring: The government has expanded its early detection network to monitor wild birds. Sampling in Alaska is focused on species that are thought to have the highest chance of bringing the virus to North America: those that migrate to and from wintering areas in the Russian Far East and Southeast Asia.Diagnostic tests: In collaboration with the Centers for Disease Control and Prevention (CDC), the Food and Drug administration recently approved a new laboratory test that can detect H5 flu viruses within a few hours. In April, the FDA provided the biotechnology industry with guidance for evaluating performance and writing product labeling for in-vitro diagnostic tests.Flu-tracking software: The CDC developed two pandemic modeling software programs—FluSurge and FluAid–for communities and hospitals.Public communication: Leavitt reported that content on the cross-government Web site, pandemicflu.gov, has increased 25% in the last 3 months and that over the last several months HHS has held roundtable talks on avian and pandemic flu with major broadcast and cable networks.”While we have accomplished much in a short period of time, the race we are in is not a sprint, but a marathon,” Leavitt wrote.See also:Leavitt’s report “Pandemic Planning Update II”http://www.flu.gov/professional/pdf/panflu20060313.pdfMar 15, 2006 CIDRAP News article “Leavitt vows action on flu vaccine technology”
Sep 5, 2008 (CIDRAP News) – Amid concern about rising resistance to oseltamivir (Tamiflu) in influenza A/H1N1 viruses, a Dutch team this week reported the death of a leukemia patient who was infected with an H1N1 virus that was resistant to the antiviral drug.In a letter in this week’s New England Journal of Medicine (NEJM), the Dutch authors said the case suggests that oseltamivir-resistant H1N1 viruses can cause disease, despite evidence from animal studies that the resistance mutation makes the viruses much less dangerous. The letter said the man’s virus was also resistant to amantadine, an older antiviral drug.On Aug 20, the World Health Organization (WHO) reported that 31% of influenza A/H1N1 isolates from 16 countries that conducted recent tests carried the H274Y mutation, which confers resistance to oseltamivir. Resistance levels ranged from 100% (10 of 10 isolates) in Australia to 13% (4 of 32 isolates) in Chile.Emergence of the oseltamivir-resistant H1N1 virus was first noted in Norway in January, and since then researchers have found the virus in 35 countries, including the United States and Canada.The spread of the oseltamivir-resistant H1N1 virus has puzzled experts because it has not been clearly linked to treatment with the drug.In the case report, authors from Erasmus University Medical Center in Rotterdam wrote that a 67-year-old man who was on chemotherapy in a 3-year battle with chronic lymphocytic leukemia was hospitalized with shortness of breath, a dry cough, and fever. On his second hospital day, he experienced acute respiratory failure, and his physicians placed him on a ventilator and started empirical antibiotic treatment.Computed tomography (CT) revealed that the patient had patchy lung infiltrates, and tests on samples from his respiratory tract showed he had influenza A/H1N1.On the sixth hospital day the man received oseltamivir, but by day 13 physicians discontinued the drug because sequence analysis of the virus revealed the H274Y mutation and there was no decrease in the viral load.The authors reported that the mutation was found in samples obtained before the patient began oseltamivir therapy. The man’s family and the hospital record revealed that he had had no contact with patients who were taking oseltamivir.On the 15th hospital day the man’s doctors prescribed amantadine, and after a few days his neutrophil count increased, a sign of bone marrow recovery, the group reported.On day 20 doctors took the patient off the ventilator and instituted zanamivir treatment. However, 2 days later the man had respiratory failure again, and his medical team put him back on the ventilator and discontinued zanamivir therapy. (Like osteltamivir, zanamivir is a neuramnidase inhibitor, but no increase in zanamivir resistance has been reported recently.)By day 26 physicians detected no influenza virus, but did note that sequence analysis showed an amantadine-resistance mutation in the viral M2 protein (L26F). They wrote that recovery of the immune system was probably responsible for clearing the virus, because the patient had received only three doses of zanamivir.A repeat CT scan taken on day 28 showed that pulmonary infiltrates had progressed. Because of the man’s poor prognosis, the ventilator was removed on day 34, and he died 3 days later.The authors cited animal studies indicating that oseltamivir resistance leaves H1N1 viruses “severely compromised.” Despite these reports, they wrote, “the case we describe suggests that this oseltamivir-resistant virus can be pathogenic, at least in an immunocompromised patient.”In an editorial published by Eurosurveillance in January, authorities said resistant viruses with the H274Y mutation had been seen in previous flu seasons but were rare and did not spread easily. But the more recent H1N1 isolates with the mutation were “fitter” and were spreading in the community, they wrote.Van der Vries E, Van den Berg B, Schutten M. Fatal oseltamivir-resistant influenza virus infection. N Engl J Med 2008 Sep 4;359(10):1074-76 [Full text]See also:Aug 25 CIDRAP News story “H1N1 viruses growing more resistant to Tamiflu”
Valamar Riviere Hotels have won the most prestigious World Travel Awards this year as well, thus confirming the title of top hotels in Croatia.Three Valamar hotels are winners in four categories. For the fifth year in a row, a hotel in Poreč Valamar Riviera 4 * was declared the leading Croatian boutique hotel, while Rabac Valamar Girandella Resort 4 * / 5 *, although only opened this year, has already been awarded as the leading Croatian resort. Hotel Valamar Lacroma Dubrovnik 4 * it is the best in as many as two categories – for the fourth year in a row it has won the prestigious award for leading business hotel, and for the fourth time it holds the title of leading hotel in Croatia (after 2013, 2015 and 2016).By winning awards in all four nominated categories, Valamar’s hotels completely surpassed the competition in which renowned Croatian hotels, many of them with a five-star category, found themselves. “Winning the World Travel Awards for the fifth year in a row is the best indicator of our ongoing commitment to providing superior service. The recognition for the leading Boutique Hotel in Croatia is the result of the continuous engagement of all former and current employees of the Valamar Riviera Hotel and is a great motivation for the whole team to continue with its excellent work in the coming years. “, said the director of the Valamar Riviera Hotel, Marko Miš.Photo: Valamar Lacroma DubrovnikThe award for the best business hotel is proof that Valamar Lacroma Dubrovnik achieves top results in congress tourism, as well as that it continuously works on improving the quality of service, said Ivica Sabljić, director of Valamar Lacroma Dubrovnik, adding that the World Travel Awards is a confirmation of all employees. to do a great job and that Valamar Lacroma Dubrovnik was and remains the first choice among congress hotels in Croatia “When you receive such an award in the first year of business, the honor is much higher, as is the responsibility to justify this recognition. With this year’s investment, Valamar Riviera has turned Rabac into a top holiday destination, which our guests and the profession have recognized as an exceptional value. This is a reward to all of us who work tirelessly to provide superior service and guest satisfaction” concluded Karmela Višković, director of Valalamar Girandella Resort.The World Travel Awards have been awarded since 1993, and for the 24th year in a row it has been recognizing and rewarding world achievements in the tourism sector. It is praised by the Wall Street Journal as the Oscar of the travel industry, and the World Travel Awards cover a wide range of categories. Candidates are chosen by the votes of professionals from the tourism industry, so it is a great honor to be in competition for this prestigious statuette